# OnCo record ken-kato (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/ken-kato/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "ken-kato" ;
  schema:name "Ken Kato"@en ;
  schema:description "Japanese oncologist who led ATTRACTION-3 and KEYNOTE-590, bringing immunotherapy to oesophageal cancer."@en ;
  schema:url <https://onco.cc/people/ken-kato/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Kato%20K%5BAuthor%5D%20esophageal%20nivolumab%20OR%20pembrolizumab> ;
  onco:tag "esophageal", "immunotherapy", "japan" ;
  schema:jobTitle "Chief, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo" ;
  onco:cancers <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:institutions <https://onco.cc/institutions/ncc-japan/> ;
  onco:trials <https://onco.cc/trials/keynote-590/> ;
  schema:affiliation <https://onco.cc/institutions/ncc-japan/> .